Xabier Pérez Aizpurua

MD FEBU Robotic Oncologic Surgery Fellow @uclh 🇬🇧| Former @Hospital_FJD Urology Trainee 🇪🇸| PhD Candidate @UAM_Madrid School of Medicine and Surgery 🏛️

[Charles Jiang MD, MPH @CharlesJiangMD]

1/
The new New England Journal of Medicine paper on transdermal estradiol is a great reminder of a question my attending asked during fellowship:

Why does STAMPEDE keep producing practice-changing trials?

The real answer sits in its MAMS design.

[Diego Barreiro @DBarreiro4]

Seguiremos comparando prostatectomias versus RT+ADT en pacientes de alto riesgo… aun sabiendo que luego de más de 2 años de ADT cerca del 50% de los pacientes seguirán castrados de por vida?

We will continue comparing prostatectomy versus RT + ADT in high-risk patients… even knowing that after more than 2 years of ADT, near 50% of patients will remain permanently castrated?

@APCCC_Lugano
@piet_ost
@declangmurphy

[Toni Choueiri, MD @DrChoueiri]

IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU clinical trials in 2025!

1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO

https://t.co/mbl2VKLZ2N

[Ramiro Cabello @ramiro_cabello_]

Hoy el Dr @xab12PA se licencia!! 🏥👨🏻‍🎓
Finaliza su formación en #Urologia @Hospital_FJD
Han sido 5 años de intenso trabajo, estudio y aprendizaje quirúrgico.
Un residente brillante que será un urólogo sensacional.
Enhorabuena!!! Zorionak!!!

[Nature Medicine @NatureMedicine]

As presented at #ASCO25: In the phase 3 CREST trial, the combination of subcutaneous sasanlimab, an anti-PD-1 inhibitor, with BCG induction and maintenance treatment significantly improved event-free survival vs. standard of care therapy https://t.co/RzkuicwrI5

[Tom Powles @tompowles1]

The positive CREST study (BCG + Sasanlimab) in NMIBC was published today (Neal Shore et al). #ASCO25

[Tom Powles @tompowles1]

At #ASCO25 : New Nectin4/PD1 combo data with response rates similar to EVP in bladder cancer. Also DV/toripalimab is better than chemo (press release). There multiple ways of beating 1st line chemo in UC. As chemo becomes less relevant a key question is around ADC sequencing

[Oscar Tahuahua @OscarTahuahua]

Excellent review in @JCO_ASCO 🌟
Management of testicular cancer, from early stage to refractory disease.

- Overview of treatment de-escalation, emerging biomarkers & survivorship care.
@OncoAlert

[Kevin Li @kevndli]

Excited to share our latest work, now out in European Urology!

We followed >166k prostate cancer survivors (1999–2019) using SEER-Medicare. RP+EBRT had the highest risk of urinary adverse events. EBRT surpassed RP at 10 yrs (with BT) & 14 yrs (alone).

https://t.co/GyqW2GmAWl

[Carmen GEnguita @CarmenGEnguita]

Gracias a La Razón por este espacio donde comparto mi visión sobre el presente y futuro de la Urología.
📰 Lee la entrevista completa:
🔗 https://t.co/apktDIfqr1
#CarmenAEU #EleccionesAEU2025 #UrologíaConPropósito

[Andrew J. Hung, MD, FACS @AjhungMD]

HOT OFF THE PRESS

New @JAMASurgery original article from our team

Surgical Performance Metrics for 1-Year Patient-Reported Outcomes After Radical Prostatectomy. Using performance metrics (technical skills and surgical gestures) collected from videos, we are able to anticipant clinical outcomes one year after surgery. Data from 28 surgeons and 5 international centers.

Funded through the National Cancer Institute (NCI)

https://t.co/3DMecsRWGU

@jimhumd @VickersBiostats @geoffsonn @alvincgoh #ChristianWagner #VipPatel

@CS_Urology @CSCancerCenter @WCMUrology @MSKCancerCenter @StanfordUrology @AmerUrological @AmCollSurgeons

[UroToday.com @urotoday]

Radical cystectomy vs bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: Results from the comparison of intravesical therapy and surgery as treatment. The #CISTO study. Presented by John Gore, MD, MS, FACS @UW. #AUA25 written coverage by @chavarriagaj @UofT > https://t.co/kpOoHUT2W5 @AmerUrological

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Our patients have spoken! #AUA25

At 12 mos, patients who underwent cystectomy reported better overall well-being – mental, emotional, and financial!

Physical function was comparable between bladder-sparing therapy and radical cystectomy.

@BladdCancerUS @angiesmith_uro

[Maarten Albersen @MaartenAlbersen]

Radical cystectomy vs bladder-sparing: QOL better (!) and less anxiety in radical cystectomy in the large prospective observational CISTO study. Surprising results and food for thought! Congrats @angiesmith_uro and team on an impressive effort. @AmerUrological

[NEJM @NEJM]

Original Article: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer (BARCODE1 study) https://t.co/unjcDVktiF

Editorial: A Polygenic Risk Score in Practice https://t.co/xjmiEM9i0N

#Oncology

[UroToday.com @urotoday]

Encore results: #BOND003 Cohort C – A Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for BCG-Unresponsive High-Risk #NMIBC with CIS. Presentation by Shreyas Joshi, MD, MPH @EmoryUniversity. #SESAUA25 written coverage by @zklaassen_md > https://t.co/NEX6sI5lFd @SES_AUA

[Ramiro Cabello @ramiro_cabello_]

#TULA Fulguración láser endoscópica ambulatoria 🔫 es una opción tto. ⏩️ CVNMI recidivas pequeñas Ta BG/G1 @Uroweb #Guidelines

[Ramiro Cabello @ramiro_cabello_]

Sesión residentes #UroFJD "Face to face" Linfadenectomía en el cáncer de próstata @drtufetjaumot Vs @xab12PA 🥊🥊

[Adam B. Weiner, MD @Adam_Weiner535]

💸💰💵💲
The cost of treating #bladdercancer is astounding

👇Check out the latest review in @EUplatinum

"The Financial Burden of Localized and Metastatic Bladder Cancer"📉

🔗https://t.co/Ifc3GJ5Z4S

@shilpaonc @CaPsurvivorship @UrogerliMD @UroMoschini @pcvblack @AndreaNecchi @MRoupret @DrShariat @spsutkaMD @UroDocAsh

[Pfizer Inc. @pfizer]

We are pleased to announce positive topline event-free survival results from our Phase 3 study in patients with BCG-naïve, high-risk non-muscle invasive #BladderCancer (NMIBC). Learn more: https://t.co/vUN32aaA1r